Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Cyclophosphamide 911Carboplatin 788pembrolizumab 749Paclitaxel 745Bevacizumab 717Cisplatin 709Gemcitabine 621Docetaxel 585Rituximab 559Radiotherapy 548Dexamethasone 512Nivolumab 492Doxorubicin 446Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 328Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × PF-06840003 × Clear all
NCT02764151 2020-01-27

First in Patient Study for PF-06840003 in Malignant Gliomas

Pfizer

Phase 1 Terminated
17 enrolled 35 charts
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡